免疫检查点抑制剂安全性研究及不良反应防治  

Safety Study and Prevention of Adverse Reactions of Immune Checkpoint Inhibitors

作　　者：任晓蕾[1] 詹轶秋[1] 张春燕[1] 黄琳[1] 张晓红[1] REN Xiao-lei;ZHAN Yi-qiu;ZHANG Chun-yan;HUANG Lin;ZHANG Xiao-hong(Department of Pharmacy,Peo-ple′s Hospital,Peking University,Beijing 100044,China)

机构地区：[1]北京大学人民医院药学部,北京100044

出　　处：《中国药学杂志》2022年第21期1855-1859,共5页Chinese Pharmaceutical Journal

摘　　要：目的探讨免疫检查点抑制剂相关不良反应的发生特点,为临床用药安全提供依据。方法汇总整理我院2020年1月至2022年4月报告的免疫检查点抑制剂相关的不良反应病例进行分析和再评价。结果25例免疫检查点抑制剂相关不良反应涉及药物包括卡瑞利珠单抗8例、信迪利单抗6例、替雷利珠单抗4例、度伐利尤单抗3例、帕博利珠单抗3例及纳武利尤单抗1例。其中严重程度为严重的13例(52%),一般的12例(48%)。25例报告中男性19例,女性6例,最小年龄26岁,最大年龄81岁,平均年龄(62.40±15.38)岁。原患疾病包括肺癌、骨肿瘤、食管癌、膀胱癌、肝癌及胰腺癌。不良反应临床表现以免疫相关肺炎、内分泌毒性及心脏毒性为主。药品不良反应(ADR)发生时间从用药当天到首次用药后329 d不等。结论临床应关注免疫检查点抑制剂的安全性问题,只有妥善管理好免疫治疗相关不良反应,才能更好的实现肿瘤免疫治疗。OBJECTIVE To explore the characteristics of adverse reactions related to immune checkpoint inhibitors,and to provide reference for rational use of drugs.METHODS The adverse reaction cases related to immune checkpoint inhibitors reported in our hospital from January 2020 to April 2022 for analysis and re-evaluation were summarized Summarize the adverse reaction cases related to immune checkpoint inhibitors reported in our hospital from January 2020 to April 2022 for analysis and re-evaluation.RESULTS The 25 immune checkpoint inhibitor-related adverse reactions involved camrelizumab(8 cases),sintilimab(6 cases),tislelizumab(4 cases),durvalumab(3 cases),pembrolizumab(3 cases)and nivolumab(1 case).Among them,13 cases(52%)were severe and 12 cases(48%)were normal.Among the 25 cases reported,there were 19 males and 6 females,the youngest age was 26 years old,the oldest age was 81 years old,and the average age was(62.40±15.38)years old.Primary diseases include lung cancer,bone tumor,esophageal cancer,bladder cancer,liver cancer and pancreatic cancer.The main clinical manifestations of adverse reactions were immune-related pneumonia,endocrine toxicity and cardiotoxicity.The occurrence time of ADR ranged from the day of administration to 329 days after the first administration.CONCLUSION Clinical attention should be paid to the safety of immune checkpoint inhibitors.Only by properly managing the adverse reactions related to immunotherapy can tumor immunotherapy be better achieved.

关 键 词：免疫检查点抑制剂 免疫治疗相关不良反应 安全用药 

分 类 号：R95[医药卫生—药学]